Gamida Cell Ltd. Completes Enrollment for Phase I/II Study of Second Pipeline Product NiCord® for Hematological Malignancies

Published: Sep 19, 2012

JERUSALEM--(BUSINESS WIRE)--Gamida Cell, a leader in adult stem cell expansion technologies and products, announced today that it has completed enrollment for a Phase I/II clinical trial of NiCord, the company’s second pipeline product. NiCord is in development as an experimental treatment for a series of indications that potentially could be cured with a bone marrow transplantation including hematological malignancies (blood cancer), sickle cell disease, thalassemia, severe autoimmune diseases and metabolic diseases. The clinical trial announced today ( identifier NCT01221857) is studying NiCord as an alternative investigational treatment for hematological malignancies (HM). A combined total of 11 patients were transplanted at Duke University Medical Center and at Loyola University Medical Center. Dr. Mitchell E. Horwitz of Duke University Medical Center is the principal investigator. Final results of the Phase I/II study are expected within 6 months. The company is also actively enrolling for a Phase I/II study of NiCord as an experimental treatment for sickle cell, a genetic blood disease ( identifier NCT01590628).

Back to news